OGN

OrganonB

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

The constructive case is still mostly deal-driven: primary-source evidence supports a pending early-2027 Sun Pharma close, while MIUDELLA, Tofidence label expansion, and biosimilars growth provide some downside support if closing takes time.

Posture

Constructive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta -0.2.

What can break

Established Brands and legacy women’s health products continue to face pricing pressure, market contraction in China, and shipment timing volatility [#SEC-8K-2026-04-30].

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $13.30 · Bull $14.00 · Bear $10.80

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-07-10 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade B · Constructive

Confidence Medium · Net Neutral

Target $12.33

Why

Momentum63 · Δ7d -11.4

Value71 · Δ7d -0.2

Sentiment42 · Δ7d -3.1

So what

Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Lead driver: Value · See fundamentals

Momentum

26% active weight

Current posture

7d trendFlat

Δ7d

-11.4

Δ21d

-31.1

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.2

Δ21d

+0.1

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-3.1

Δ21d

-3.1

Why this grade

Composite grade B. Momentum 63.2 / Value 70.7 / Sentiment 42.5

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$3.55B

Beta

0.54

Shares Out

262.61M

P/E (TTM)

3.9

P/S (TTM)

0.31

P/FCF (TTM)

4.74

Rev YoY

-3.5%

EPS YoY

+66.6%

Gross Margin

+53.2%

Op Margin

+11.1%

Net Debt

$8.23B

Current Ratio

1.97

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology